推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 東北制藥年報(bào)顯示公司2015年?duì)I業(yè)收入38.34億元，同比下降11.51%，歸屬于上市公司股東的凈利潤-3.84億元，同比下降541.41%。
公司表示，由于主導(dǎo)產(chǎn)品維生素C及維生素C系列的銷售價(jià)格同比下降，導(dǎo)致毛利減少7160萬元。國家醫(yī)改政策變化，對(duì)公司部分制劑產(chǎn)品銷量造成影響，銷量同比下降減少毛利8100萬元。預(yù)告期內(nèi)，公司未發(fā)生土地變現(xiàn)事項(xiàng)。上年同期土地等資產(chǎn)移交增加公司同期利潤8300多萬元。預(yù)告期內(nèi)，公司細(xì)河廠區(qū)部分產(chǎn)品陸續(xù)投產(chǎn)，折舊費(fèi)用和運(yùn)營成本增加。今年食品藥品監(jiān)督管理局、公安部和國家衛(wèi)生計(jì)生委聯(lián)合發(fā)布關(guān)于擴(kuò)大第二類精神藥品管理范圍的公告，對(duì)藥品生產(chǎn)、經(jīng)營企業(yè)的銷售、購銷管理等提出了較高的要求，對(duì)公司部分產(chǎn)品的銷售造成影響，導(dǎo)致毛利同比減少4900萬元。
